Engineers Gate Manager LP Cardiff Oncology, Inc. Transaction History

Engineers Gate Manager LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.17 - $2.61 $287,313 - $640,929	-245,567 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.11 - $7.25 $518,146 - $1.78 Million	245,567 New	245,567 $609,000
Q3 2021 Nov 15, 2021	SELL	$5.01 - $7.58 $100,746 - $152,426	-20,109 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$6.65 - $10.04 $414,321 - $625,532	-62,304 Reduced 75.6%	20,109 $134,000
Q1 2021 May 17, 2021	BUY	$9.1 - $19.57 $749,958 - $1.61 Million	82,413 New	82,413 $763,000

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $170M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.